Pensar Medical, an innovator in negative pressure wound therapy (NPWT), announced a strategic partnership with Centurion Therapeutics for the distribution of the Microdoc sNPWT (single-use negative pressure wound therapy) platform. This collaboration aims to enhance patient care and expand access to advanced wound management.
The Microdoc sNPWT system offers cost-effective and efficient treatment for chronic and acute wounds. Combining Pensar Medical’s innovative technology with Centurion Therapeutics’ extensive distribution channel, the partnership seeks to drive widespread adoption of the Microdoc platform and deliver the proven benefits of sNPWT via over 500 sales professionals in more than 600 sites of care.
The annual market for sNPWT is approximately $400mm and is growing by more than 20% annually. This growth is supported by clinical research that sNPWT can reduce surgical site infections and improve healing. Surgical site infections cost the US healthcare system over $3.3 billion dollars annually and sNPWT devices, like MicroDoc, may cut this risk by >50%.
“We are thrilled to partner with Centurion Therapeutics,” said Jason Bandy, CEO of Pensar Medical. “Their strong presence and rapid growth in the inpatient market, combined with our novel NPWT technology, will enable us to reach more patients and improve outcomes.”
Robert Goodwin, President and CEO of Centurion Therapeutics, affirmed, “Adding the Microdoc sNPWT system to our product portfolio aligns perfectly with our commitment to providing comprehensive wound and surgical management solutions nationwide. We are excited about the opportunity to offer this innovative product to our distribution partners and their customers.”
